- Home
- SBAC vs BIIB Comparison
SBAC vs BIIB Comparison
Compare SBAC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBAC
- BIIB
- Stock Information
- Founded
- SBAC 1989
- BIIB 1978
- Country
- SBAC United States
- BIIB United States
- Employees
- SBAC N/A
- BIIB N/A
- Industry
- SBAC Real Estate Investment Trusts
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- SBAC Real Estate
- BIIB Health Care
- Exchange
- SBAC Nasdaq
- BIIB Nasdaq
- Market Cap
- SBAC 20.2B
- BIIB 18.7B
- IPO Year
- SBAC 1999
- BIIB 1991
- Fundamental
- Price
- SBAC $198.08
- BIIB $142.38
- Analyst Decision
- SBAC Buy
- BIIB Buy
- Analyst Count
- SBAC 15
- BIIB 25
- Target Price
- SBAC $245.47
- BIIB $183.05
- AVG Volume (30 Days)
- SBAC 1.1M
- BIIB 1.8M
- Earning Date
- SBAC 11-03-2025
- BIIB 10-30-2025
- Dividend Yield
- SBAC 2.25%
- BIIB N/A
- EPS Growth
- SBAC 71.76
- BIIB 31.67
- EPS
- SBAC 8.15
- BIIB 10.45
- Revenue
- SBAC $2,724,524,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- SBAC $6.88
- BIIB $2.00
- Revenue Next Year
- SBAC $2.72
- BIIB N/A
- P/E Ratio
- SBAC $24.22
- BIIB $13.61
- Revenue Growth
- SBAC 1.82
- BIIB 3.36
- 52 Week Low
- SBAC $185.45
- BIIB $110.04
- 52 Week High
- SBAC $252.64
- BIIB $192.16
- Technical
- Relative Strength Index (RSI)
- SBAC 53.60
- BIIB 46.57
- Support Level
- SBAC $185.45
- BIIB $142.20
- Resistance Level
- SBAC $189.67
- BIIB $160.20
- Average True Range (ATR)
- SBAC 3.62
- BIIB 4.83
- MACD
- SBAC 1.51
- BIIB -1.15
- Stochastic Oscillator
- SBAC 89.92
- BIIB 28.17
About SBAC SBA Communications Corporation
SBA Communications owns a portfolio of about 45,000 wireless towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, who install equipment to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by the top few mobile carriers. It owns more than 17,000 towers in the US, which account for about 75% of leasing revenue. Internationally, SBA's largest presence is in Brazil, where it owns roughly 10,000 towers. SBA operates as a real estate investment trust.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.